Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Payables (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Payables for 4 consecutive years, with $943000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Payables fell 27.18% to $943000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $943000.0, a 27.18% decrease, with the full-year FY2025 number at $943000.0, down 27.18% from a year prior.
  • Payables was $943000.0 for Q4 2025 at Spruce Biosciences, down from $1.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $3.4 million in Q1 2023 to a low of $682000.0 in Q2 2024.
  • A 4-year average of $1.7 million and a median of $1.4 million in 2022 define the central range for Payables.
  • Peak YoY movement for Payables: skyrocketed 210.91% in 2023, then crashed 61.13% in 2024.
  • Spruce Biosciences' Payables stood at $1.4 million in 2022, then surged by 133.66% to $3.3 million in 2023, then plummeted by 61.13% to $1.3 million in 2024, then decreased by 27.18% to $943000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Payables are $943000.0 (Q4 2025), $1.4 million (Q3 2025), and $807000.0 (Q2 2025).